GU Cancers Symposium 2012 - A Randomized phase II study of OGX-427 + prednisone vs. prednisone alone in patients with chemotherapy-naive metastatic castration resistant prostate cancer - Poster

Presented by K. Chi,^1,2 S. Hotte,³ S. Ellard,⁴ J. Gingerich,⁵ A. Joshua,⁶ E. Yu,⁷ and M. Gleave,² at the 2012 Genitourinary Cancers Symposium - February 2 - 4, 2012 - San Francisco Marriott Marquis - San Francisco, California
¹BC Cancer Agency, Vancouver, BC ²Vancouver Prostate Centre, Vancouver, BC ³Juravinski Cancer Centre, Hamilton, ON ⁴BC Cancer Agency – Southern Interior, Kelowna, BC ⁵CancerCare Manitoba, Winnipeg, AB ⁶Princess Margaret Hospital, Toronto, ON ⁷University of Washington, Seattle, WA

Related Item:

A randomized phase II study of OGX-427 + prednisone vs. prednisone alone in patients with chemotherapy-naïve metastatic castration resistant prostate cancer - Session Highlight

View Full 2012 GU Cancers Symposium Coverage